Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2008 | Original Article

Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients

Authors: Tetsuji Shinohara, Naohiko Takahashi, Kunio Yufu, Futoshi Anan, Tetsuya Kakuma, Masahide Hara, Mikiko Nakagawa, Tetsunori Saikawa, Hironobu Yoshimatsu

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2008

Abstract

Purpose

Increased serum interleukin-6 (IL-6) levels are associated with an increased risk of cardiovascular disease, and cardiovascular autonomic dysfunction is associated with high mortality in type 2 diabetic patients. However, the relationship between IL-6 levels and cardiovascular autonomic dysfunction has not been fully elucidated. The aim of this study was to determine whether serum IL-6 levels are associated with cardiovascular autonomic dysfunction in type 2 diabetic patients.

Methods

Eighty type 2 diabetic patients who did not have organic heart disease were categorized into a high IL-6 group (>2.5 pg/ml, n = 40, age 59 ± 12 years) or a non-high IL-6 group (<2.5 pg/ml, n = 40, 61 ± 12 years). Cardiac autonomic function was assessed by baroreflex sensitivity, heart rate variability, plasma norepinephrine concentrations and ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy.

Results

The body mass index values (BMI), fasting insulin levels and homeostasis model assessment index values were higher in the high IL-6 group than in the non-high IL-6 group (p < 0.01). Early and delayed ¹²³I-MIBG myocardial uptake values were lower (p < 0.01), and the percent washout rate of ¹²³I-MIBG was higher (p < 0.05) in the high IL-6 group than in the non-high IL-6 group. Furthermore, multiple regression analysis revealed that the IL-6 level was independently predicted by the BMI and the myocardial uptake of ¹²³I-MIBG during the delayed phase.

Conclusions

The results indicate that elevated IL-6 levels are associated with depressed cardiovascular autonomic function and obesity in type 2 diabetic patients.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.PubMedCrossRef

Bennet AM, Prince JA, Fei GZ, Lyrenäs L, Huang Y, Wiman B, et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003;171:359–67.PubMedCrossRef

Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799–805.PubMedCrossRef

Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784–9.PubMedCrossRef

Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391–9.PubMedCrossRef

Sandler S, Bendtzen K, Eizirik DL, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990;126:1288–94.PubMedCrossRef

Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850–5.PubMed

La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478–84.PubMedCrossRef

Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43:313–7.PubMedCrossRef

10.

Takahashi N, Anan F, Nakagawa M, Yufu K, Shinohara T, Tsubone T, et al. Hypoadiponectinemia in type 2 diabetes mellitus in men is associated with sympathetic overactivity as evaluated by cardiac 123I-metaiodobenzylguanidine scintigraphy. Metabolism 2007;56:919–24.PubMedCrossRef

11.

Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55:65–85.PubMedCrossRef

12.

Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. Diabetes Care 1998;21:2116–22.PubMedCrossRef

13.

Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450–8.PubMedCrossRef

14.

Anan F, Masaki T, Yonemochi H, Takahashi N, Nakagawa M, Eshima N, et al. Abdominal visceral fat accumulation is associated with the results of (123)I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients. Eur J Nucl Med Mol Imaging 2007;34:1189–97.PubMedCrossRef

15.

Sato T, Nishinaga M, Kawamoto A, Ozawa T, Takatsuji H. Accuracy of a continuous blood pressure monitor based on arterial tonometry. Hypertension 1993;21:866–74.PubMed

16.

Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874–7.PubMed

17.

Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006;98:14–8.PubMedCrossRef

18.

Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587–93.PubMedCrossRef

19.

Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–42.PubMedCrossRef

20.

Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679–84.PubMedCrossRef

21.

Mantysaari M, Kuikka J, Mustonen J, Tahvanainen K, Vanninen E, Lansimies E, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine. Diabetes 1992;41:1069–75.PubMedCrossRef

22.

Schnell O, Muhr D, Weiss M, Kirsch CM, Haslbeck M, Tatsch K, et al. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus. J Diabetes Its Complicat 1997;11:307–13.CrossRef

23.

Gerritsen J, TenVoorde BJ, Dekker JM, Kingma R, Kostense PJ, Bouter LM, et al. Measures of cardiovascular autonomic nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia 2003;46:330–8.PubMed

24.

Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy a noninvasive method to demonstrate myocardial adrenergic nerve system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252–8.PubMedCrossRef

25.

Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995;26:1594–9.PubMedCrossRef

26.

Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006;13:34–42.PubMedCrossRef

27.

Sakata K, Shirotani M, Yoshida H, Kurata C. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med 1999;40:6–11.PubMed

28.

Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997;46:67–76.

29.

Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161–8.PubMedCrossRef

30.

Ziegler D, Weise F, Langen KJ, Piolot R, Boy C, Hubinger A, et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41:443–51.PubMedCrossRef

31.

Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999;99:546–51.PubMed

32.

Yin F, Wang YY, Du JH, Li C, Lu ZZ, Han C, et al. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J Mol Cell Cardiol 2006;40:384–93.PubMedCrossRef

33.

Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001;14:231–6.CrossRef

34.

Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298–303.PubMedCrossRef

35.

Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355–61.PubMedCrossRef

36.

Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001;58:671–83.PubMed

37.

Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083–9.PubMedCrossRef

38.

Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 2004;31:1353–5.PubMedCrossRef

39.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661–7.PubMedCrossRef

Title: Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients
Authors: Tetsuji Shinohara
Naohiko Takahashi
Kunio Yufu
Futoshi Anan
Tetsuya Kakuma
Masahide Hara
Mikiko Nakagawa
Tetsunori Saikawa
Hironobu Yoshimatsu
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0809-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2008

Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by 18F-18 FDG PET/CT and bone marrow biopsy

Role of cardiac nuclear imaging in the management of critically ill patients

[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults

Nuclear Cardiology and Integrated Cardiovascular Imaging Today-2008 18–20 September 2008, in Cesena, Italy

Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213